Grifols, S.A. (GRFS)
- Previous Close
6.58 - Open
6.64 - Bid 6.52 x 800
- Ask 6.55 x 800
- Day's Range
6.46 - 6.64 - 52 Week Range
5.30 - 12.15 - Volume
754,930 - Avg. Volume
2,169,737 - Market Cap (intraday)
5.567B - Beta (5Y Monthly) 0.68
- PE Ratio (TTM)
65.40 - EPS (TTM)
0.10 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 3, 2021
- 1y Target Est
15.65
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
www.grifols.com23,744
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: GRFS
Performance Overview: GRFS
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GRFS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GRFS
Valuation Measures
Market Cap
5.54B
Enterprise Value
16.43B
Trailing P/E
68.42
Forward P/E
15.02
PEG Ratio (5yr expected)
0.27
Price/Sales (ttm)
0.63
Price/Book (mrq)
0.71
Enterprise Value/Revenue
2.49
Enterprise Value/EBITDA
13.90
Financial Highlights
Profitability and Income Statement
Profit Margin
0.90%
Return on Assets (ttm)
2.14%
Return on Equity (ttm)
2.20%
Revenue (ttm)
6.59B
Net Income Avi to Common (ttm)
59.31M
Diluted EPS (ttm)
0.10
Balance Sheet and Cash Flow
Total Cash (mrq)
646.04M
Total Debt/Equity (mrq)
133.58%
Levered Free Cash Flow (ttm)
-1.26B
Research Analysis: GRFS
Analyst Price Targets
Fair Value
Analyst Recommendations
Earnings
Research Reports: GRFS
Analyst Report: Grifols, S.A.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
RatingBullishPrice TargetAnalyst Report: Grifols, S.A.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
RatingBullishPrice TargetAnalyst Report: Grifols, S.A.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
RatingBullishPrice TargetAnalyst Report: Grifols, S.A.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.
RatingBullishPrice Target